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Supplementary Table 1. The list of the best 181 alternative splice events in breast cancer – 
available as a separate text file.  
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The table contains following columns:  
Gene_name(known_genes=156) – official gene symbol.  
tr_cl(n=164) – transcript cluster id as in the Affymetrix Human Junction Array 
annotation files.  
GroupID(splice_events=181) – unique splice event ID, compiled of probesets ID the 
event has been detected with.  
PSIDcount – number of individual probesets with which the splice events has been 
detected. 
rank_by_NSI –probesets rank based on the variability scorei,j,k (see Methods section of 
the paper).  
percent_of_FIRMA_score_>0.3 – percent of the samples having FiRMA weight score 
of >0.3 
UCSC_link – link to the UCSC browser showing custom track with the best splice 
events reported in this study. 
B_L_diff_in_MeanSI – difference between means of NSI values of (luminal) subtype 
and two other subtypes together.   
B_L_p.adjust – Benjamini-Hochberg adjusted p-value associated with the previous 
column.  
caludinLOW_L_diff_in_MeanSI - difference between means of NSI values of claudin-
low and luminal subtypes cells.   
claudinLOW_L_p.adjust - Benjamini-Hochberg adjusted p-value associated with the 
previous column. 
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Subtype_specific – code for statistically significant differences in splicing based on the 4 
previous columns. 0 – no difference; 1 – significant difference according to either of the 
two comparisons in the previous columns; 2 – significant difference according to both 
comparisons in the previous columns.  
plasma membrane – shows whether the gene product is localized to the plasma 
membrane according to the Gene Ontology. 
Accession_corresponding_to_isoform_specific_toClaudinLow, isoform_uniq_PS_Ids, 
isoform_uniq_PS__coordinates - explicitly identify isoforms specific to claudin low cells 
within genes localized to plasma membrane. 
Supplementary Table 2. Primer sequences for RT-PCR. 
Gene Forward Primer Reverse Primer Sizes 
FLNB TGGAACCTATGACATCTTCTACACA GACCAGGTCAAAAGGCTTAAATC 244/172 
CLTC AAACTGCATGGAGGCACAATATC GGTTGTGTCTCTGTAGCTTGTTCTT 162/142 
FAT ATCTTGATCCCTGTCTTTCCAAG TCATAGTTGGGGAACTCTTGTATGT 156/121 
TJP1 GCCACAACCAATTCATAGAATAGAC AACATGGTTCTGCCTCATCATTT 346/106 
FER1L3 TTGGAACAACATATCTACACCTCTC GCTTCCATAAAGATTCAGGTAACAA 167/128 
UTRN AGGAAGTTGAAAGCCTTAGAAAGAG CTTTGAAAATCGAGCATTTATCCAT 390/207 
SLK AAACAGCAGAAACAGACTATCGAAC ATGATCTTTTTCAGAGAGCCATCTA 216/123 
MYO6 AATCCCAACAGCAAGCAGTTCT CACAAGAAGTATTGATGGTATCACG 294/225 
FAM62B CTTTCCTCTGCATTGCTGATCTT ACTGACATCTGGACAACAGGATT 203/141 
DST-1 TCCAAATGACATAGAAAAAGAGTGG 
TTTCAGGAATAAAAATGCACAGTAG 
TCAGTTTGTCTTCACAGATGACACT 248/151 
DST-2 TCATGGACCTAAGGACTCGATATAC ACCTTCGGAAGTTCTTCCTCTACT 
TTGCTGATATTTGATACCCATTTTT 
427/331 
PLEC1 AGCCATCCAGAACGAGATCAG 
AGAGAACCAGCTCGGAGGA 
AAGTGGGTCAACAAGCACCT 117/86 
KIF21A GAAATAACCAGTGCTACCCAAAAC GTTTAAAGGAGCATCCTCATCAGT 165/144 
CLSTN1 (57nt) ATCCATCCAAGATAGAAACTCAGC AGACAGTCGATCACCTTCTTATCC 202/145 
CLSTN1 (30nt) ATAGTCACAGAGAACGACAACACC GATTTATCCACTACCACTGCATCA 179/149 
ST7 AGAAAGCCTGGAGAGAGAGAAAC AAATAATTTTTCTGCTTCAGCAATG 209/140 
MARK3 CGAGGCTCCACTAATCTCTTTAGTA CTTCTTTGTTTTCATCTTTTTGCTC 284/212 
PLOD2 TGAAAGGAACTATTTTGTTCGTGAT CAGAGGTCATTGTTATAATGGGAAG 225/162 
VPS39 GTGGGAACCAAACAAGGACAT CTGCTGAATCTTTTTGGAGAA 150/117 
Fox2 qPCR GTGTACACAGCCGACCCCTA CACTTCAGTAGGGGGCAAATC 112 
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Deep sequencing of cell lines transcriptomes using Illumina technology. 
Library construction and sequencing. Total RNA was extracted from MCF7 and BT549 cells 
using Qiagen’s RNeasy Mini Kit.  An early version of Illumina’s mRNA-Seq protocol was used 
to prepare the sequencing libraries.  mRNA was isolated from the total RNA extracts using 
Dynal oligo(dT) beads from Invitrogen.  The mRNA isolates were then fragmented using 
Ambion’s RNA fragmentation kit.  Next, mRNA fragments were converted to double stranded 
cDNA fragments using random hexamer primers and the SuperScript™ Double-Stranded cDNA 
Synthesis Kit from Invitrogen. For the next steps, Illumina’s genomic DNA sequencing protocol 
was followed to produce the MCF7 and BT549 sequencing libraries.  Fragments of 200bp +/- 
25bp were selected in the gel based ligation purification step.   Sequencing was performed on 
Illumina’s Genome Analyzer using one flowcell loading lane 1-4 with the BT549 library and 
lane 5-8 with the MCF7 library. The Illumina analysis pipeline was used for image analysis and 
base calling to obtain reads of 36nt long.  19,553,572 reads were obtained for the BT549 sample 
and 18,747,831 for MCF7.  ELAND was used to align the reads to the genome. 
Mapping of sequencing reads. Each cell line was sequenced using 4 Illumina flow cell lanes 
producing a total of 19,553,572 and 19,747,831 reads of 36 bp length for the BT549 and MCF7 
cell lines respectively. The reads have been trimmed to 32 bp removing last 4 bp of poorer 
quality and mapped to the entire collection of probeset sequences from Human Junction Array 
using MAQ software 35. To ensure adequate mapping we have compiled two reference sets of (i) 
junction sequences (JUCs) and (ii) exonic sequences (PSRs). The JUC reference set was 
assembled from sequences of probesets on the array by taking 29 bp of sequence on each side of 
an exon junction producing sequences of 58 bp length. A small fraction of JUCs (~8 %) were 
between 32 bp and 58 bp size with at least 16 bp on each side of the junction. For PSR reference 
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set we have used full probesets sequences. The majority of PSR sequences (93%) ranged in size 
from ~40bp to ~700bp. Mapping was done requiring no more than 2 mismatches and MAQ 
alignment quality score of 20 for both JUC and PSR sequences, and at least 3 bp span of a splice 
junction. Supplementary Table 3 summarizes mapping results of Illumina/Solexa data for MCF7 
and BT549 cell lines.  
Expression estimates. Probesets expression level has been derived from read count data (number 
of reads mapped to the reference sequence) by normalizing for the reference sequence length. 
Since the minimal reference sequence length was 32 bp we defined normalized read count 
(NRC) data as:  
NRC=RC*32/L  
where RC is the raw read count data and L is the length of reference sequence in bp. Whole 
genome NRC data has been filtered to remove unreliable low coverage probesets from further 
analyses. We have required a probeset to have the sum of NRC between two cell lines of  >= 1, 
which roughly corresponded to 2 mapped reads per average 58 bp JUC probe. Next, NRC data 
has been log2 transformed to make it comparable with the microarray log2 scale expression 
summaries: 
 Expression = log2 (NRC +1). 
Determination of Alternative Splicing (AS calls)
Expression estimates using both Illumina technology and Affymetrix microarrays have been 
used in identical manner to generate AS calls. First, log2 expression values for each of the two 
cell lines have been transformed to NSI values. Second, probeset-wise SI_score differences have 
been calculated for the pair of cell lines for each platform. A probeset, which had NSI score 
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difference at least one standard deviation away from the mean of SI differences across all 
probesets in that gene was called AS.  

Comparison of splicing measured by microarrays and sequencing technology.  
High throughput sequencing was used as an independent approach for detection of alternative 
splicing in breast cancer cell lines.   We obtained ~ 19 million 32 basepair Illumina sequencing 
reads of the transcriptomes for two different subtypes of breast cancer, including one basal B 
(BT549) and one luminal (MCF7) line. Specifically we compared (1) the best 152 genes/392 
probesets (termed best set) and (2) a strongly variable set (variable set) of 78,050 probesets from 
1760 transcript clusters from the selection process (see “Selection of highly variable probe sets” 
section of the Methods). To test the overall agreement between expression profiles measured by 
the HJAY and Illumina platforms we compared estimated expression level (absolute signal) and 
relative expression (BT549 vs MCF7) for the 78K probesets. The relative expression of BT549 
vs MCF7 (log2 ratios) of illumina vs HJAY was 0.78.    
 
For validation both microarray and Illumina/Solexa data for sets 1 and 2 have been processed to 
generate differential alternative splicing calls (AS calls) using SI measures. The summary of AS 
calls within two platforms is in Supplementary Table 4. Within the best set out of 302 AS calls 
made for the Affymetrix platform, 98 (32%) have been also made by Illumina platform. In 
comparison, the variation set rate was 15.6%. Overall, within the best set, 25% of probesets had 
AS calls in both platforms. Within the variable set only 4% were called from both platforms 
(Supplementary Figure 1). Thus, the best set of the best AS candidates was significantly enriched 
with differential splicing signal from both platforms (Chi-squared test, 2=489.5, df = 1, p-value 
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< 2.2e-16). Notably, even though the 78K set included differentially spliced probesets (the set 
originates from step 1 of the selection process and 4% of probesets exhibited differential splicing 
with both platforms), their removal did not significantly improve correlations. This observation 
supports our assumption that 78K is an unbiased representative sampling of the whole genome 
data. 
Supplementary figure 1. Illumina sequencing validation of the AS microarray predictions  
 
A) Pie charts summarize detection of AS in two cell lines, MCF7 and BT549, using the best 
validation set of 392 probesets and representative (reference) set of 78,050 probesets. Affymetrix 
calls, Illumina calls and Both calls refer to the number of probesets, which showed differential 
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signals between the two cell lines in a given platform or in two platforms simultaneously. Single 
calls refer to the number of probesets, which showed differential signal in a given platform, but 
not in the other. No call refers to absence of differential signal in both platforms. B) A list of best 
392 probesets have been stratified according to average expression level of corresponding 
transcripts and sets of transcripts from each bin have been validated using Illumina data.  
 
Supplementary Table 3. Summary of Illumina/Solexa reads mapping onto the collection of 
probe sets from HJAY array.  
 
Supplementary Table 4. Summary of AS detection with microarray and sequencing platforms.
The table summarizes detection of AS in two cell lines, MCF7 and BT549, using the best 
validation set of 392 probesets and representative (reference) set of 78,050 probesets. Affymetrix 
calls, Illumina calls and Both calls refer to the number of probesets, which showed differential 
BT549 MCF7 
Number of JUC probe sets 252,741 
Number of PSR probe sets 307,435 
Total number of reads 19,553,572 19,747,831
Reads that map to JUC 1,593,103 1,533,075 
Reads that map to PSR 10,239,925 8,872,672 
Number of JUC probes with at least one 
mapped read 101,290 103,180 
Number of PSR probes with at least one 
mapped read 143,536 145,746 
 
AS calls validation set reference set
Affymetrix calls 302 18149
Illumina_calls 115 12045
both_calls 98 2832
Affymetrix_single_calls 204 15317
Illuminal_single_calls 17 9213
no_call 73 50688
total 392 78050
validation rate 32.45% 15.60%
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signals between the two cell lines in a given platform or in two platforms simultaneously. Single 
calls refer to the number of probesets, which showed differential signal in a given platform, but 
not in the other. No call refers to absence of differential signal in both platforms.  
 
Supplementary Figure 2. Networks and Pathways associated with splice variants in breast 
cancer cell lines.  
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Top network highly saturated with AS genes is shown at the top and the merged network 
(composed of three top networks) is shown below. A network is a graphical representation of the 
molecular relationships between molecules. Molecules are represented as nodes, and the 
biological relationship between two nodes is represented as an edge (line). All edges are 
supported by at least 1 reference from the literature, from a textbook, or from canonical 
information stored in the Ingenuity Pathways Knowledge Base. The intensity of the node color 
indicates the degree of up- (red) or down- (green) regulation. Nodes are displayed using various 
shapes that represent the functional class of the gene product. Edges are displayed with various 
labels that describe the nature of the relationship between the nodes (e.g., P for phosphorylation, 
T for transcription). For the shown merged network MYC, Actin, EGFR are the major nodes. 
The main functions associated with the merged network are cytoskeleton organization and 
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biogenesis and cell signaling. There was also a significant enrichment for a number of pathways 
such as Integrin Signaling, Tight Junction Signaling, Ephrin Receptor Signaling, Actin 
Cytoskeleton Signaling and Focal adhesion. Genes involved with differential splicing are coded 
with grey, pink and red, depending on the frequency of differential splicing (as defined by 
FIRMA).  
 
 
 
